The invention relates to novel RNA nucleic acids (aptamers) capable of inhibiting DNA methyltransferase 1 (DNMT1), enzyme involved in DNA methylation, strictly linked to tumorogenesis. The invention therefore claims the use of such aptamers for treatment of neoplastic diseases.
The global cancer therapeutics market size was valued at $98 billion in 2018 and is estimated to reach at $180 billion by 2026, registering a CAGR of 7.7%.
The global epigenetics drugs and diagnostic technologies market size was valued at $5.24 billion in 2017.
DNA methylation dominated the epigenetics market: Global Market estimated to Reach $8.88 Billion by 2030 with a GAGR of 13%
Global Increase in Cancer Prevalence
Increasing Government Funding for Healthcare. Major players: DNA methylation market is mainly dominated by several diagnostic majors, such as Exact Sciences Corporation, Illumina, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc., which offer a wide variety of diagnostics and research-based products for the detection of DNA methylation.
The Drugs market is consolidated with few players such as Celgene Corporation, Otsuka America, Inc. patent owners), Merck & Co., Inc., Novartis AG.
Physicians and surgeons
Lack of smart and safe therapeutic strategies for cancer treatment. DNA methylation is an epigenetic modification regulating gene expression.
Numerous studies have established a link between aberrant DNA methylation and cancer. In this view, the targeting of DNA methylation by specific and effective inhibitors could lead to the development of clinically relevant strategies for cancer therapy.
The developed molecules can overcome the toxicity of in-use demethylating protocols and provide high stability, selectivity and safety. High affinity and specificity
(No recognition of other DNMTs or unrelated RNA binding proteins)
No binding to human serum albumin
High stability (over 48h in 85% human serum) and safety
Low batch variability
Simple production, easy modification and cost effectiveness
No toxicity and immunogenicity, suitable for repeated doses
We are planning a start-up that will develop the nanostructure system.
The technology development plan includes:
1. The pre-clinical analysis aimed at setting the optimization of the nanoparticle system and their administration and evaluating Pharmacodynamic and Pharmacokinetic.
2. The subsequent clinical development for the evaluation of safety, dosage, efficacy and comparison with standard treatments.